| abstract |
The present invention discloses methods, compositions and kits for making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, disease susceptibility, response to therapy or prognostic assessments. More particularly, the present invention discloses methods, compositions and kits for identifying a subject with, or at risk of developing, Type 1 diabetes (T1D), or stratifying a subject with risk of development of T1D to a treatment regimen based on a biomarker profile including hematopoietic cell number or heparanase expression. |